Germany’s long-anticipated “Pillar 2,” which would launch adult-use marijuana sales as part of a limited-duration pilot project, is in danger of being abandoned, according to elected officials.
Cannabis operator Flora Growth Corp. announced an agreement with London-based Blossom Genetics to supply medical marijuana to the German market.
Increased consumer demand for American cannabis products and emerging opportunities in Europe are driving some U.S. brands to expand internationally.
A British American Tobacco subsidiary acquired roughly 4.4 million Organigram common shares and 8.5 million Class A preferred shares for gross proceeds of CA$41.5 million.
Germany’s recreational cannabis market has limited opportunity, but Bloomwell Group’s Niklas Kouparanis is bullish on the medical market.
IM Cannabis Corp., a medical marijuana company operating in Israel and Germany, said it has regained compliance with the minimum-bid price requirement to list on the Nasdaq stock exchange.
Aphria RX, the Neumünster, Germany-based subsidiary of Tilray Brands, said Monday it received a medical marijuana cultivation license under the European country’s new Cannabis Act.
